Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ADRX | 3 | neutral | 2/10 | Carl L. Gordon, Ph.D., CFA, a representative of OrbiMed Advisors, filed an initial Statement of Beneficial Ownership (Fo | Sep 24, 2026 |
| ADRX | 3 | neutral | 2/10 | Zhen Li, Ph.D., the President and CEO of ADARx Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership | Sep 24, 2026 |
| JAGX | SC 13G/A | bearish | 5/10 | Joshua Mailman filed an amended Schedule 13G disclosing a 9.99% passive stake in Jaguar Health, Inc. as of September 12, | Sep 24, 2026 |
| RVMD | CLUSTER | bearish | 4/10 | Eight Revolution Medicines insiders sold a total of $6.07M in open-market sales over a one-week window, including the CO | Sep 24, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Two CRISPR Therapeutics insiders, Director Ali Behbahani and General Counsel James Kasinger, sold a combined $1.41M in o | Sep 24, 2026 |
| ACAD | 8-K | bullish | 6/10 | Acadia Pharmaceuticals announced Phase 3-enabling topline results from the Phase 2 portion of the RADIANT trial evaluati | Sep 24, 2026 |
| BMRA | S-3 | bearish | 5/10 | Biomerica filed an S-3 shelf registration to register 1,403,705 shares of common stock for resale by selling stockholder | Sep 24, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview Ho | Sep 24, 2026 |
| SNTI | DEFM14A | bearish | 7/10 | Senti Biosciences is seeking stockholder approval of a merger with a Celadon Partners affiliate that will result in no u | Sep 24, 2026 |
| SKYE | CLUSTER | neutral | 3/10 | Two insiders at Skye Bioscience sold a combined $108K in open-market sales over a one-week window. The sales are modest | Sep 24, 2026 |
| UTHR | CLUSTER | bearish | 4/10 | CEO Martine Rothblatt sold ~$10.7M in open-market shares over Sept 18-22, 2026, alongside option exercises. EVP Paul Mah | Sep 24, 2026 |
| SKYE | SC 13D/A | bearish | 6/10 | 5AM Partners VII, LLC and affiliated entities filed Amendment No. 6 to their Schedule 13D on Skye Bioscience, reporting | Sep 24, 2026 |
| BGM | 6-K | bearish | 5/10 | BGM Group Ltd. announced a 30-for-1 reverse share split, effective October 1, 2026, to regain compliance with Nasdaq's m | Sep 24, 2026 |
| NBTX | 6-K | bearish | 6/10 | Nanobiotix filed its H1 2026 half-year report, showing a net loss of €34.3 million (vs. €5.4 million in H1 2025) driven | Sep 24, 2026 |
| RZLT | 8-K | bearish | 6/10 | Rezolute reported Q4 FY2026 results with a net loss of $20.5M ($-0.20 EPS), missing consensus estimates of $-0.14 by 42. | Sep 24, 2026 |
| PRFX | SC 13D | bullish | 7/10 | S.H.N. Financial Investments Ltd., an Israeli investment firm controlled by Hadar Shamir and Nir Shamir, filed a Schedul | Sep 24, 2026 |
| JSPR | 25-NSE | bearish | 7/10 | Nasdaq filed a Form 25-NSE to delist Jasper Therapeutics' redeemable warrants (each ten warrants exercisable for one sha | Sep 24, 2026 |
| BKHA | 8-K | mixed | 6/10 | Black Hawk Acquisition Corp. (BKHA) entered into a comprehensive financing package with Meteora Select Trading Opportuni | Sep 24, 2026 |
| SAFX | 425 | bearish | 6/10 | XCF Global has postponed its special meeting for the second time, from September 24 to October 5, 2026, to vote on the p | Sep 24, 2026 |
| NBTX | 6-K | neutral | 5/10 | Nanobiotix reported H1 2026 financial results with a net loss of €34.3M ($0.70/share) vs €5.4M ($0.11/share) in H1 2025, | Sep 24, 2026 |
| NBTX | PRESS-RELEASE | neutral | 4/10 | Nanobiotix reported H1 2026 financial results with a net loss of €34.3M (€0.70 per share) vs €5.4M (€0.11) in H1 2025, d | Sep 24, 2026 |
| RZLT | PRESS-RELEASE | bearish | 6/10 | Rezolute reported Q4 FY2026 EPS of -$0.20, a 42.9% miss vs consensus of -$0.14, with no revenue. The miss was driven by | Sep 24, 2026 |
| REGN | PRESS-RELEASE | neutral | 1/10 | Regeneron Pharmaceuticals, Inc. announced it will report its Q3 2026 results on October 30, 2026. | Sep 24, 2026 |
| PRME | PRESS-RELEASE | bullish | 7/10 | Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin | Sep 24, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab granted 13,794 restricted stock units and 13,331 warrants to employees as routine equity compensation. The RSUs h | Sep 24, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K disclosing that Maya Martinez-Davis, President US, acquired 9.414 notional ADS at $50.72 within | Sep 24, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Eight insiders at Pharvaris sold a total of ~$7.35M in open-market sales over a 7-day window, including the President ($ | Sep 24, 2026 |
| PHVS | CLUSTER | bearish | 7/10 | Eight Pharvaris insiders sold a total of $7.35M in open-market sales over a one-week window, including the President ($3 | Sep 24, 2026 |
| JAGX | 424B5 | bearish | 5/10 | Jaguar Health filed Supplement No. 8 to its ATM prospectus, disclosing that it has approximately $9.82 million remaining | Sep 24, 2026 |
| CELU | PRESS-RELEASE | mixed | 6/10 | Celularity announced an initial closing of a private placement of senior secured convertible notes and warrants generati | Sep 24, 2026 |